Achillion Pharma (ACHN) Announces Positive SVR12 Data for Odalasvir, AL-335, and Simeprevir Phase 3 in Genotype 1 HCV
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
- After-hours movers: Alpine Immune Sciences, Costco, and more
- Midday movers: Delta, Taiwan Semiconductor rise; Hexcel falls
Achillion Pharma (ACHN) trading halted with news pending
September 23, 2016 11:45 AM EDTAchillion Pharma (NASDAQ: ACHN) trading halted with news pending.
... MoreJanssen Announces Submission of Sirukumab BLA to FDA as RA Treatment
September 23, 2016 8:01 AM EDTJanssen Biotech, Inc. (Janssen) announced the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) seeking approval of sirukumab for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). RA is a chronic, systemic inflammatory condition that affects approximately 1.5 million Americans.1
We are committed to deepening our understanding of rheumatoid arthritis with the goal of applying new scientific learnings to advance treatments like sirukumab for people living with this inflammatory rheumatologic disease, said Newman Yeilding, M.D., Head of Immunology Development, Janssen Research & Development, LLC. We are pleased to submit an application for sirukumab to the U.S. Food and Drug Administration and look forward to working with the agency with the goal of... More
